Candel Therapeutics, Inc. (CADL) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-15

Key Insights

Candel presented extended follow-up data from a Phase 3 clinical trial of aglatimagene besadenovec for localized prostate cancer at the American Urological Association 2026 Annual Meeting, suggesting progression toward potential regulatory approval.
The company held a simultaneous investor webcast on the same day as the medical conference presentation, indicating efforts to manage investor communications and market perception around clinical trial results.
This is a Regulation FD disclosure filing with furnished exhibits that are explicitly not incorporated by reference, limiting the legal liability and forward-looking statement implications typically associated with filed documents.

Want the newest filings?

This analysis covers the filing from 2026-05-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-14

Candel Therapeutics announced Q1 2026 financial results on May 14, 2026, with the full details provided in a press release attached as Exhibit 99.1, though the specific financial metrics are not disclosed in this 8-K cover document.
The filing is designated as furnished rather than filed under Section 18 of the Exchange Act, meaning it carries reduced liability exposure and is not automatically incorporated into other SEC filings unless expressly referenced.
Paul Peter Tak, M.D., Ph.D., FMedSci is identified as President and CEO, indicating stable leadership at the biotech company as of the filing date.

Filed: 2026-03-12

Candel Therapeutics announced its Q4 2025 and full-year 2025 financial results, highlighting the company's progress and performance.
The company did not provide any forward-looking guidance or commentary on its pipeline or upcoming milestones in the 8-K filing.
No material changes to Candel's leadership, agreements, or other significant corporate events were reported in this 8-K filing.

Filed: 2026-02-23

Candel Therapeutics, Inc. has launched a public offering of 18.3 million shares of its common stock, with an additional 2.8 million shares available through an overallotment option.
The company plans to use the estimated $93.5 million in net proceeds to support critical launch readiness, medical affairs, pre-commercialization, and ongoing development of its lead candidate CAN-2409 for prostate and lung cancer.
Assuming the base offering amount, the company expects its cash and cash equivalents to fund operations and capital expenditures into the first quarter of 2028.

Filed: 2026-02-19

Candel Therapeutics entered into a $100 million purchase and sale agreement with RTW Investments for its prostate cancer drug CAN-2409 upon FDA approval, providing upfront capital and a tiered royalty structure.
The agreement includes a ratchet provision that increases the royalty rate if certain sales thresholds are not met, and a buy-out option for Candel Therapeutics in the event of a change of control.
Candel Therapeutics reported preliminary cash and cash equivalents of approximately $119.7 million as of December 31, 2025, indicating a strong cash position ahead of the potential FDA approval and product launch.

Other reports for Candel Therapeutics, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.